RE:RE:RE:RE:RE:RE:RE:RE:RE:hope we’re not being set up for Great reply Snobei. As you stated, there were VERY FEW "hard" 3-point MACE events in the post-hoc analyses of ASSERT, SUSTAIN and ASSURE. Most of the 5-point MACE events that comprised those post-hoc analyses were the "soft" coronary revascularization/hospitalization for unstable angina or heart failure category. In post-hoc of ASSURE and SUSTAIN, there were a total of 35 5-point MACE events in the entire population. Of these, only 8 were 3-point MACE events. If one looks at just diabetics, there were a total of 14 5-point MACE events and ONLY 3 were 3-point MACE events.
There are now two peer-reviewed published papers on the post-hoc analysis of ASSURE/SUSTAIN and ASSURE/SUSTAIN/ASSERT that provide itemized details on how many of each MACE event occured. I've broken down the ASSURE/SUSTAIN post-hoc analysis before in
this post; however, it was based upon post-hoc MACE data presented at ESC 2014 that was just slightly different than what is in the Gilham et al. Atherosclerosis 2016 article. I don't have access to the Nicholls et al. Am J Cardiovasc Drugs. 2018 post-hoc that also included ASSERT. Probably mostly the same though.
https://www.ncbi.nlm.nih.gov/pubmed/29027131
https://www.ncbi.nlm.nih.gov/pubmed/26868508
BearDownAZ